The association between adverse events and outcome under checkpoint inhibitors: Where is the deal?

The association between adverse events and outcome under checkpoint inhibitors: Where is the deal?

Recent reports have put into evidence the possibility of a link between immune-related adverse events (IRAEs) and treatment outcome, patients drawing a benefit from treatment being also exposed to the risk to develop toxicity.A still unanswered question remains the biological origin(s) which can sus...

Full description

Bibliographic Details
Main Authors: Gerard Milano, Federico Innocenti, Joseph Ciccolini
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Translational Oncology
Subjects:
Immunotherapy
Checkpoint inhibitors
Immune-related adverse events
Treatment efficacy
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523320304447
id doaj-5bdadbebb1ce4ea79a98386d1617c3ef
record_format Article
spelling doaj-5bdadbebb1ce4ea79a98386d1617c3ef2020-12-25T05:07:45ZengElsevierTranslational Oncology1936-52332021-01-01141100952The association between adverse events and outcome under checkpoint inhibitors: Where is the deal?Gerard Milano0Federico Innocenti1Joseph Ciccolini2UNS EA 7497 Nice University, Centre Antoine Lacassagne, 33 avenue de Valombrose, 06189 Cedex 2, France; Corresponding author.UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USASMARTc School of Pharmacology, Marseille, FranceRecent reports have put into evidence the possibility of a link between immune-related adverse events (IRAEs) and treatment outcome, patients drawing a benefit from treatment being also exposed to the risk to develop toxicity.A still unanswered question remains the biological origin(s) which can sustain and explain such a relationship.The purpose of this review paper is to lay out different potential contributions which can help to understand the IRAEs-outcome link and to propose clinical perspectives taking advantage of this association.In this respect, pharmacokinetics aspects, immunological and immunogenetics implications have been taken into consideration.http://www.sciencedirect.com/science/article/pii/S1936523320304447ImmunotherapyCheckpoint inhibitorsImmune-related adverse eventsTreatment efficacy
collection DOAJ
language English
format Article
sources DOAJ
author Gerard Milano
Federico Innocenti
Joseph Ciccolini
spellingShingle Gerard Milano
Federico Innocenti
Joseph Ciccolini
The association between adverse events and outcome under checkpoint inhibitors: Where is the deal?
Translational Oncology
Immunotherapy
Checkpoint inhibitors
Immune-related adverse events
Treatment efficacy
author_facet Gerard Milano
Federico Innocenti
Joseph Ciccolini
author_sort Gerard Milano
title The association between adverse events and outcome under checkpoint inhibitors: Where is the deal?
title_short The association between adverse events and outcome under checkpoint inhibitors: Where is the deal?
title_full The association between adverse events and outcome under checkpoint inhibitors: Where is the deal?
title_fullStr The association between adverse events and outcome under checkpoint inhibitors: Where is the deal?
title_full_unstemmed The association between adverse events and outcome under checkpoint inhibitors: Where is the deal?
title_sort association between adverse events and outcome under checkpoint inhibitors: where is the deal?
publisher Elsevier
series Translational Oncology
issn 1936-5233
publishDate 2021-01-01
description Recent reports have put into evidence the possibility of a link between immune-related adverse events (IRAEs) and treatment outcome, patients drawing a benefit from treatment being also exposed to the risk to develop toxicity.A still unanswered question remains the biological origin(s) which can sustain and explain such a relationship.The purpose of this review paper is to lay out different potential contributions which can help to understand the IRAEs-outcome link and to propose clinical perspectives taking advantage of this association.In this respect, pharmacokinetics aspects, immunological and immunogenetics implications have been taken into consideration.
topic Immunotherapy
Checkpoint inhibitors
Immune-related adverse events
Treatment efficacy
url http://www.sciencedirect.com/science/article/pii/S1936523320304447
work_keys_str_mv AT gerardmilano theassociationbetweenadverseeventsandoutcomeundercheckpointinhibitorswhereisthedeal
AT federicoinnocenti theassociationbetweenadverseeventsandoutcomeundercheckpointinhibitorswhereisthedeal
AT josephciccolini theassociationbetweenadverseeventsandoutcomeundercheckpointinhibitorswhereisthedeal
AT gerardmilano associationbetweenadverseeventsandoutcomeundercheckpointinhibitorswhereisthedeal
AT federicoinnocenti associationbetweenadverseeventsandoutcomeundercheckpointinhibitorswhereisthedeal
AT josephciccolini associationbetweenadverseeventsandoutcomeundercheckpointinhibitorswhereisthedeal
_version_ 1724371310579023872

Similar Items